Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.66 |
| ▸ | BTK | Q06187 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CTSK | P43235 | 2/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28804033 | 1.00 | GAA (0.68) | GAAEPHX1BTKCA1CA2 | |
| Ethane SCHEMBL27689700 | 0.98 | GAA (0.66) | GAAEPHX1BTKCA1CA2 | |
| SCHEMBL1829584 | 0.98 | BTK (0.67) | GAAEPHX1BTKCA1CA2 | |
| Bicarbonate SCHEMBL1457456 | 0.96 | BTK (0.66) | GAAEPHX1BTKCA1CA2 | |
| Bicarbonate SCHEMBL1580534 | 0.94 | BTK (0.68) | GAAEPHX1BTKCA1CA2 | |
| SCHEMBL369297 | 0.94 | BTK (0.72) | GAAEPHX1BTKCA1CA2 | |
| SCHEMBL999662 | 0.93 | GAA (0.60) | GAAEPHX1BTKCA1CA2 | |
| Methyl Alcohol SCHEMBL9686628 | 0.92 | BTK (0.70) | GAAEPHX1BTKCA1CA2 | |
| Acetic Acid Methyl Ester SCHEMBL7025319 | 0.91 | BTK (0.59) | GAAEPHX1BTKCA1CA2 | |
| Bicarbonate SCHEMBL486564 | 0.90 | BTK (0.73) | GAAEPHX1BTKCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117800875-A | Preparation method of trans- (N-Boc-4-aminocyclohexyl) acetic acid | 泰州精英化成医药科技有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-1682702-A | Method for preparing pharmaceutical composition capable of inhibiting postinfectious viral protease | ALBERT LAB (US) | 2005-10-19 | — | — | CN | claimed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-119013277-A | TYK2 degrading agent and application thereof | 凯麦拉医疗公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-113302184-B | 1,3, 4-Oxadiazolinone compounds and medicaments | 日本新药株式会社 | 2024-11-22 | — | — | CN | disclosed |
| CN-118696041-A | Macrocyclic BTK inhibitors | 克罗斯费尔肿瘤学控股有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-118574613-A | Methods of treating cancer | 凯麦拉医疗公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-5856307-A | Peptide derivatives as kininogenase inhibitors | ASTRA AKTIEBOLAG (SE) | 1999-01-05 | — | — | US | disclosed |
| US-5847135-A | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-12-08 | — | — | US | disclosed |
| US-5783563-A | Method for treatment or prophylaxis of venous thrombosis | ASTRA AKTIEBOLAG | 1998-07-21 | — | — | US | disclosed |
| US-5780631-A | ANTICOAGLUANT | ASTRA AKTIEBOLAG (SE) | 1998-07-14 | — | — | US | disclosed |
| US-5723444-A | ENZYME INHIBITORS AND ANTICOAGULANTS | ASTRA AB (SE) | 1998-03-03 | — | — | US | disclosed |
| US-5716929-A | THERAPY FOR INFLAMMATION, AUTOIMMUNE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0672653-B1 | Process for producing isocyanates | MITSUBISHI GAS CHEMICAL CO (JP) | 1998-01-14 | — | — | EP | disclosed |
| CN-1025676-C | Non-peptidic renin inhibitors | PFIZER (US) | 1994-08-17 | — | — | CN | disclosed |
| CN-1034366-A | The blood vessel tension peptide protoenzyme inhibitor of non-peptide | PFIZER (US) | 1989-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | GAA 36/4885EPHX1 4056/4885BTK 2743/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | GAA 2026/4885EPHX1 4238/4885BTK 2244/4885 |
| US-20240239749-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | GAA 2874/4885EPHX1 1506/4885BTK 2827/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | GAA 3046/4885EPHX1 4857/4885BTK 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.